第一阶段：主要研究目标：评估MBS314在复发/难治性多发性骨髓瘤（R/RMM）患者中的安全性和耐受性,并观察MBS314的剂量限制性毒性（DLT），确定在人体的最大耐受剂量（MTD）（如有）或最佳生物剂量（OBD），为后续临床研究确定推荐的Ⅱ期剂量（RP2D）。第二阶段：主要研究目标：评估有效性。

开始日期2024-01-29

申办/合作机构

康源博创生物科技（北京）有限公司

[+1]

100 项与康源博创生物科技（北京）有限公司相关的临床结果

登录后查看更多信息

0 项与康源博创生物科技（北京）有限公司相关的专利（医药）

登录后查看更多信息

项与康源博创生物科技（北京）有限公司相关的文献（医药）

2025-04-21·Cancer Research

Abstract 2133: KA-2887-LD38: a novel bispecific antibody-drug conjugate (ADC) targeting both EGFR and PD-L1

作者: Liang, Jiabei ; Ning, Jinying ; Nian, Weihong ; He, Feng ; Wu, Guojin ; Zhou, Qing ; Xu, Chuanying ; Guo, Zhengcheng

AbstractPD-L1 is widely expressed across various cancer types and suppresses immune responses against tumor cells. EGFR is also highly expressed in many solid tumors and plays a key role in driving tumor growth. Targeting the PD-1/PD-L1 signaling pathway and the EGF/EGFR signaling pathway using antagonistic antibodies or ADCs has shown promising results in cancer therapy. However, both approaches can lead to undesirable "on-target/off-tumor" effects. Co-expression of PD-L1 and EGFR is rare in normal tissues but is commonly observed in most PD-L1-expressing tumor cells. In this study, we developed a bispecific antibody, KA-2887, using our common light chain antibody discovery platform to target both EGFR and PD-L1. This bispecific antibody was then used to construct the ADC KA-2887-LD38. KA-2887-LD38 has a conventional IgG1 structure, conjugated with LD-38, an Escugen proprietary ADC platform composed of TopIi payload and highly hydrophilic stable cleavable linker. It binds to EGFR with an affinity of 3.7 nM and to PD-L1 with an affinity of 0.6 nM. KA-2887-LD38 effectively blocks both the interaction between EGF and EGFR, and the interaction between PD-1 and PD-L1.The expression of EGFR on tumor cells enhances the inhibitory effect of KA-2887-LD38 on the PD-1/PD-L1 interaction, and vice versa. Compared to monoclonal antibodies targeting PD-L1, KA-2887-LD38 shows a much faster internalization rate when binding to tumor cells co-expressing EGFR and PD-L1. In vitro, KA-2887-LD38 demonstrates cytotoxicity against tumor cells expressing either EGFR and PD-L1 together or EGFR alone, but has a weaker effect on tumor cells expressing only PD-L1. Tumor cells co-expressing EGFR and PD-L1 are more sensitive to KA-2887-LD38. Additionally, KA-2887-LD38 exhibits strong bystander killing activity. Xenograft mouse tumor models show that KA-2887-LD38 strongly inhibits the growth of various tumor types, including NSCLC, head and neck squamous cell carcinoma, and esophageal squamous cell carcinoma. Toxicity studies on KA-2887-LD38 are ongoing. The results suggest that KA-2887-LD38 holds significant potential for the treatment of a variety of solid tumors.Citation Format:Guojin Wu, Chuanying Xu, Weihong Nian, Zhengcheng Guo, Jiabei Liang, Feng He, Qing Zhou, Jinying Ning. KA-2887-LD38: a novel bispecific antibody-drug conjugate (ADC) targeting both EGFR and PD-L1 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2133.

2025-04-21·Cancer Research

Abstract 5981: Over 200! The largest BaF3-EGFR engineering cell lines collection, a useful platform for novel drug discovery

作者: Wang, Guoqian ; Tang, Yao ; Peng, Yao ; Hao, Feng ; Ning, Jinying ; Xu, Jingxiao ; Lv, Tingduo

AbstractThe epidermal growth factor receptor (EGFR) is a cell-surface receptor tyrosine kinase that belongs to the ERBB family, which includes HER1 (EGFR), HER2, HER3, and HER4. Each of these receptors has three key layers: an input layer, a signal-processing core, and an output layer. EGFR is activated primarily through ligand binding, with ligands such as EGF, TGF-alpha, HB-EGF, AR, EPR, BTC, and epigen. However, mutations or overexpression of EGFR can lead to ligand-independent activation. Once activated, EGFR triggers various downstream signaling pathways, such as PI3K-AKT, JAK-STAT, RAS-MEK/ERK, and PLC-gamma-PKC, which enhance cell proliferation, survival, and resistance to cell death.The overexpression or increased activity of EGFR is linked to several cancers, including non-small cell lung cancer (NSCLC), colon cancer, head and neck cancer (HNC), pancreatic cancer, breast cancer, and brain cancer. Recognizing EGFR as a driver gene has accelerated the development of targeted anticancer therapies, such as monoclonal anti-EGFR antibodies (cetuximab, panitumumab) and small molecule receptor tyrosine kinase inhibitors (TKIs). The first generation of EGFR TKIs, like gefitinib and erlotinib, specifically target mutations such as L858R and exon 19 deletions. To address resistance to these early inhibitors, second-generation EGFR TKIs (afatinib, dacomitinib) were developed. The EGFR T790M mutation is a major mechanism of resistance to both first and second-generation TKIs. Osimertinib, a third-generation TKI, was approved for use in EGFR-mutated NSCLC following the failure of first- and second-generation TKIs, although the EGFR C797S mutation limits its effectiveness. Fourth-generation EGFR TKIs, including BLU-945 and BBT-176, are under clinical evaluation but are not yet approved.We have created more than 200 Ba/F3-EGFR engineered cell lines, making this the largest in vitro and in vivo platform for drug discovery with the widest range of mutant cells. These cell lines include almost all clinically significant EGFR mutations, such as common mutations like L858R and exon 19 deletions, as well as rare mutations like L861Q, S768I, and combinations of mutations like L858R/T790M, Del19/T790M, and triple mutations. These Ba/F3-EGFR engineered cell lines are valuable tools for developing and assessing next-generation EGFR inhibitors and for studying newly acquired resistance mutations in EGFR.Citation Format:Yao Tang, Guoqian Wang, Tingduo Lv, Jingxiao Xu, Yao Peng, Jinying Ning, Feng Hao. Over 200! The largest BaF3-EGFR engineering cell lines collection, a useful platform for novel drug discovery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5981.

2025-04-21·Cancer Research

Abstract 6088: The bispecific antibody KA-5377, targeting CD19 and 4-1BB, specifically enhances T cell activity against lymphoma

作者: Peng, Hao ; Ning, Jinying ; Wu, Guojin ; Hao, Feng ; Liang, Jiabei

AbstractKA-5377 is a novel bispecific antibody (BsAb) developed to target CD19 and human 4-1BB, addressing the challenge of dose-limiting toxicity associated with traditional 4-1BB agonist cancer immunotherapy. CD19, which is highly expressed in lymphoma, serves as an ideal target for this therapy. By restricting 4-1BB activation to the tumor microenvironment, KA-5377 aims to mitigate systemic toxicity. The 4-1BB nanobody used in KA-5377 was developed through our nanobody antibody discovery platform. KA-5377 is designed in an IgG1 format with a LALA mutation in the Fc region to eliminate ADCC (antibody-dependent cellular cytotoxicity) and ADCP (antibody-dependent cellular phagocytosis) activity, ensuring that the antibody’s activity is focused on stimulating 4-1BB in T cells. The bispecific antibody contains two 4-1BB nanobodies at the C-terminal that engage 4-1BB signaling upon binding, and two Fabs at the N-terminal that bind to CD19 expressed on tumor cells. KA-5377 demonstrates high avidity for lymphoma tumor cells expressing CD19, while binding to 4-1BB expressed on 293T cells with significantly lower avidity. Notably, 4-1BB signaling is strongly activated only when the antibody binds to CD19 on tumor cells, with much weaker activation observed when CD19 binding is absent. The difference in EC50 (effective concentration for 50% activation) between the CD19-bound and non-bound states is approximately 100-fold, compared to only a 2-fold difference observed with the benchmark bispecific antibody Englumafusp Alfa.When combined with a low concentration of CD3 antibody to stimulate T cell activation, KA-5377 significantly enhances T cell activation and proliferation in co-culture assays using primary T cells isolated from human PBMCs. In PBMC-humanized immunodeficient mouse tumor models, KA-5377 improves the cytotoxic activity of bispecific antibodies targeting CD20 and CD3 against WSU-DLCL2 tumors, which highly express CD19. Additionally, KA-5377 exhibits a normal half-life in the blood of Balb/c mice and demonstrates good developability. Toxicity studies are currently ongoing. In conclusion, KA-5377, developed using our nanobody antibody discovery platform, represents a promising preclinical candidate for the treatment of Relapsed/Refractory B-cell lymphoma.Citation Format:Guojin Wu, Jiabei Liang, Hao Peng, Feng Hao, Jinying Ning. The bispecific antibody KA-5377, targeting CD19 and 4-1BB, specifically enhances T cell activity against lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6088.

项与康源博创生物科技（北京）有限公司相关的新闻（医药）

2025-03-29

·医药笔记

中国企业引领ADC创新前沿

▎Armstrong2025年美国癌症研究协会年会（AACR）即将于4月25-30日在美国芝加哥举行，最近会议摘要已经公开，中国创新密集亮相。以ADC领域为例，绝大部分的报告来自中国药企，创新ADC接近100款，覆盖各种技术路线和靶点上的创新，真正开始引领ADC的创新前沿。双靶点ADC为ADC领域当前最热门的方向之一，百力司康、百奥赛图、博锐生物、橙帆医药、多禧生物、恒瑞医药、基石药业、金赛药业、康宁杰瑞、康源博创、联进生物、启德医药、石药集团、拓济生物、先声药业、信达生物、映恩生物、亲和力生物等多家企业布局。双毒素ADC也开始走到台前，康弘药业、亲和力生物系统布局双毒素ADC，康弘药业的KH815为全球首款进入临床阶段的双毒素ADC新药。两种payload分别为TOP1i和RAN POL2i，同时抑制RNA合成并诱导DNA双链断裂。康宁杰瑞进一步开发了双靶点双毒素ADC，即EGFR/HER3双毒素ADC新药JSKN021。传统ADC的理念是毒素经抗体结合受体介导内吞后释放，DXd-ADC则证明了旁观者效应的重要作用，宜联生物则进一步开发了非内吞ADC，靶向游离靶标VEGF，通过肿瘤微环境特异性酶来释放毒素，进一步打开了ADC药物的应用空间。维立志博开发了首款TCE的ADC，即DLL3/CD3 ADC新药LBL-058，由DLL3/CD3双抗偶联TOP1i而成，T细胞杀伤与payload细胞毒杀伤效应协同。虽然TCE在少数靶点已经开始突破实体瘤，但TCE-ADC的设计无疑为突破实体瘤提供了一种全新强化设计的思路。总结从此次AACR会议来看，中国ADC无论在数量上，还是在差异化设计上，毫无疑问都在真正引领ADC的创新前沿，新靶点ADC、新靶点组合双靶点ADC、双毒素ADC、PDC、TCE-ADC、非内吞ADC等等，以及AACR会议不涉及的自免ADC（映恩生物已经进入临床阶段）等。未来几年，国产ADC的临床突破和出海交易仍然是值得期待的行业焦点所在。Armstrong技术全梳理系列GPRC5D靶点全梳理；CD40靶点全梳理；CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向；Claudin 6靶点全梳理；Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇；CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理；Ambrx技术全梳理；Vir Biotech技术全梳理；Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；科望医药技术全梳理2.0；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理；Momenta技术全梳理；NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

抗体药物偶联物AACR会议

2025-03-28

·药智网

超200款中国创新药，将亮相AACR

2025年美国癌症研究协会年会（AACR）即将于4月25-30日在美国芝加哥举行，最近会议摘要已经公开，超过200款来自中国的创新药集中亮相，无疑优势一份国产抗癌创新药出海扫货的潜在清单。ADC、双抗/多抗、小分子、PROTAC多种药物形式竞相亮相，其中ADC无疑是占比最多的药物形式。ADC药物中，有几个重要的趋势，新靶点ADC、双抗ADC、双毒素ADC大量涌现。众多ADC靶点中，消化道肿瘤的CDH17最为热门，有11款，中国作为消化道肿瘤高发国家，CDH17的大热与几年前Claudin18.2的大热如出一辙，这11款分别来自博奥信、博锐生物、橙帆医药（CDH17/Claudin18.2）、华东医药、乐普生物、礼新医药、迈威生物、拓创生物、维立志博、先声药业、宜联生物。布局双抗ADC的有百力司康、百奥赛图、博锐生物、橙帆医药、多禧生物、恒瑞医药、基石药业、金赛药业、康宁杰瑞、康源博创、联进生物、启德医药、石药集团、拓济生物、先声药业、信达生物、映恩生物、亲和力生物等。布局双毒素ADC的有多禧生物、康弘药业、康宁杰瑞、亲和力生物等。双抗/多抗也是中国药企最重要的创新方向，包括肿瘤免疫双抗、抗体融合细胞因子、TCE双抗和三抗等。许多特色技术平台和产品值得关注，如维立志博的TCE技术和一系列管线，德琪医药的新一代TCE技术，华辉安健和基石药业的PD-1/CTLA-4/VEGF三抗等。小分子热门靶点包括Pan-KRAS、Pan-RAS、WRN、KAT6、KIF18A、HPK1、PARP1等，以及许多新靶点的PROTAC等。图片来源：医药笔记<结语>从AACR上亮相的中国创新药来看，数量多、差异化特色清晰（如宜联生物针对游离靶标的VEGF ADC），其中一些产品已经完成授权出海，如映恩生物的EGFR/HER3 ADC，乐普生物的CDH17 ADC等。预计此次AACR之后，上述列表中会有更多特色产品完成授权出海合作。来源 | 医药笔记（药智网获取授权转载）撰稿 | Armstrong责任编辑 | 八角声明：本文系药智网转载内容，图片、文字版权归原作者所有，转载目的在于传递更多信息，并不代表本平台观点。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间删除。合作、投稿 | 马老师 18323856316（同微信）阅读原文，是受欢迎的文章哦

抗体药物偶联物AACR会议蛋白降解靶向嵌合体

2025-03-27

·摩熵医药

2025年AACR，超200款中国创新药闪耀亮相！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 2025年美国癌症研究协会年会（AACR）即将于4月25-30日在美国芝加哥举行，最近会议摘要已经公开，据不完全统计，今年有 95 家中国药企亮相 AACR 会议，带来了超 200 项新药研究结果，其中包括 60 项 ADC 研究、31 项双抗研究和 11 项单抗研究，其他药物类型还有多肽偶联药物、分子胶、细胞疗法、三抗、PROTAC 等。 ADC药物中，有几个重要的趋势，新靶点ADC、双抗ADC、双毒素ADC大量涌现。布局双抗ADC的有百力司康、百奥赛图、博锐生物、橙帆医药、多禧生物、恒瑞医药、基石药业、金赛药业、康宁杰瑞、康源博创、联进生物、启德医药、石药集团、拓济生物、先声药业、信达生物、映恩生物、亲和力生物等。布局双毒素ADC的有多禧生物、康弘药业、康宁杰瑞、亲和力生物等。从靶点来看，消化道肿瘤的CDH17最为热门，有11款，分别来自博奥信、博锐生物、橙帆医药（CDH17/Claudin18.2）、华东医药、乐普生物、礼新医药、迈威生物、拓创生物、维立志博、先声药业、宜联生物。百济神州首次披露了 4-1BB/GPC3 双抗 BGB-B2033，EGFR/MET 三抗 BG-T187、PRMT5 抑制剂 BGB-58067 等产品的临床前研究数据。先声药业公布了多款差异化布局的 ADC 最新研究结果，靶点涉及 CDH17、ENPP3、EGFR/cMet、cMET/B7H3 等。信达生物则首次披露了 IBI3010 的靶点为 FRα 。此外，恒瑞、翰森、齐鲁、石药等也在此次 AACR 会议上发布了重要研究数据。2025年AACR会议摘要：中国药企将披露的超 200 项新药研究结果列表小结近年来，中国创新药在 AACR 会议上的影响力持续攀升，吸引了越来越多目光。也越来越多的项目出海达成合作，中国创新药研发实力不容小觑。 END 近期热门资源获取 CGT产业现状与未来趋势蓝皮书-202406 中药行业现状与未来趋势白皮书-202407 2023年医药企业综合实力排行榜-202408 跨越国界，引领创新：中国药企出海的布局实践-202408 专利即将到期五大重磅小分子药品，国内仿制药“战况”几何?-202409 中国放射性药物市场现状分析报告-202410 合成生物产业发展前景及中国合成生物产业链上中下游企业分析-202410 中国合成生物学创投市场分析报告-202410 中国糖尿病临床诊疗与药物多渠道市场数据分析-202411 基于剂型改良的复杂注射剂分析--微球篇-202411 2024医美注射材料市场发展分析报告-20241213 国家药品集采跟踪报告-前9批次集采回顾与展望-202411 近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

抗体药物偶联物AACR会议细胞疗法蛋白降解靶向嵌合体

100 项与康源博创生物科技（北京）有限公司相关的药物交易

登录后查看更多信息

100 项与康源博创生物科技（北京）有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年05月09日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

MBS314 ( BCMA x CD3 x GPRC5D )	-	临床2期
G-02-9D7 (Kyinno Biotechnology) ( GPRC5D )	多发性骨髓瘤更多	临床前
KA-1874 ( CD112R x PD-1 x TIGIT )	肿瘤更多	临床前
H11E11-2V1 ( IL2RA )	肿瘤更多	临床前
KA-3004 ( 4-1BB x PDL1 )	实体瘤更多	临床前